title: Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats.
abstract: Autoantibodies (AABs) against the second extracellular loop of the beta1-receptor (beta1(II)-AABs) are found as a pathogenic driver in patients with idiopathic dilated cardiomyopathy, Chagas cardiomyopathy, peripartum cardiomyopathy, and myocarditis, and have been increasingly seen as a treatment target. We recently identified an aptamer (single short DNA strand) that specifically binds and neutralizes beta1(II)-AABs. Via application of this aptamer, a new treatment strategy for diseases associated with the cardio-pathogenic beta1(II)-AABs could be developed. Spontaneously hypertensive rats (SHR) positive for beta1(II)-AABs were treated five times at weekly intervals (bolus application of 2 mg/kg body weight followed by an infusion of the same amount over 20 min). SHR responded to aptamer treatment with a strong reduction in the cardio-pathogenic beta1(II)-AABs. The AABs did not substantially return within the study period. No signs for aptamer toxicity were observed by visual examination of the heart, liver, and kidney, or by measurement of plasma CK, ALT, and creatinine. The aptamer's potential for beta1(II)-AAB neutralization and consequently for cardiomyopathy treatment has been shown for the first time in vivo.
authors.affiliation: Abteilung Pathobiochemie und Medizinische Chemie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
authors.forename: Annekathrin
authors.initials: A
authors.lastname: Haberland
authors.forename: Gerd
authors.initials: G
authors.lastname: Wallukat
authors.forename: Sabine
authors.initials: S
authors.lastname: Berg
authors.forename: Angela-Martina
authors.initials: AM
authors.lastname: Schulz
authors.forename: Ernst-Joachim
authors.initials: EJ
authors.lastname: Freyse
authors.forename: Roland
authors.initials: R
authors.lastname: Vetter
authors.forename: Eckhard
authors.initials: E
authors.lastname: Salzsieder
authors.forename: Johannes
authors.initials: J
authors.lastname: Müller
authors.forename: Reinhold
authors.initials: R
authors.lastname: Kreutz
authors.forename: Ingolf
authors.initials: I
authors.lastname: Schimke
mesh_terms: D000818:Animals; D052157:Aptamers, Nucleotide / Q000008:administration & dosage* / Q000235:genetics; D001323:Autoantibodies / Q000187:drug effects* / Q000235:genetics; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D006801:Humans; D051381:Rats; D011918:Rats, Inbred SHR / Q000235:genetics; D018342:Receptors, Adrenergic, beta-1 / Q000235:genetics* / Q000276:immunology
chemical_list: D052157:Aptamers, Nucleotide; D001323:Autoantibodies; D018342:Receptors, Adrenergic, beta-1
references.citation: Eur J Heart Fail. 2012 Dec;14(12):1374-88
references.pmid: 22892122
references.citation: Curr Opin Mol Ther. 2000 Jun;2(3):258-63
references.pmid: 11249619
references.citation: Nat Rev Drug Discov. 2010 Jul;9(7):537-50
references.pmid: 20592747
references.citation: J Card Fail. 1999 Sep;5(3):246-54
references.pmid: 10496197
references.citation: Int J Cardiol. 2011 May 19;149(1):89-94
references.pmid: 20096470
references.citation: Expert Rev Clin Immunol. 2011 Sep;7(5):659-74
references.pmid: 21895478
references.citation: Circ Res. 2011 Oct 14;109(9):986-92
references.pmid: 21868696
references.citation: Eur J Heart Fail. 2013 Jul;15(7):724-9
references.pmid: 23639780
references.citation: Circulation. 2000 Feb 1;101(4):385-91
references.pmid: 10653829
references.citation: J Am Coll Cardiol. 2010 Feb 2;55(5):463-8
references.pmid: 20117461
references.citation: Biomed Biochim Acta. 1987;46(8-9):S634-9
references.pmid: 2449194
references.citation: J Clin Invest. 2004 May;113(10):1419-29
references.pmid: 15146239
references.citation: Circ J. 2012;76(10):2449-55
references.pmid: 22850243